Matti Jubouri, Abdelaziz O Surkhi, Sven Zcp Tan, Damian M Bailey, Ian M Williams, Mohamad Bashir
{"title":"腹主动脉瘤腔内治疗后囊腔消退与患者寿命的相关效应:一项国际分析。","authors":"Matti Jubouri, Abdelaziz O Surkhi, Sven Zcp Tan, Damian M Bailey, Ian M Williams, Mohamad Bashir","doi":"10.1177/02184923221129983","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Since the introduction of endovascular aortic repair (EVAR) it has become the mainstay treatment for abdominal aortic aneurysms. Several EVAR devices exist commercially, yet, the Terumo Aortic Fenestrated Anaconda™ endograft has demonstrated outstanding results. Evidence in the literature suggests that sac regression could be linked to patient survival and longevity. The main scope of this study is to evaluate sac regression and survival achieved using the Fenestrated Anaconda™ endograft and to discuss relevant literature.</p><p><strong>Materials and methods: </strong>The current study represents a nine-year cross-sectional international analysis of custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R were utilised. Pearson chi-square analysis was used to assess differences in cumulative distribution frequencies between select variables. Statistical significance for all two-tailed tests was set at <i>p </i>< 0.05.</p><p><strong>Results: </strong>A total of 5,058 patients received the Fenestrated Anaconda™ in this study, either due to unsuitable/complex anatomy for competitor devices (<i>n</i> = 3,891) or based on surgeon preference (<i>n</i> = 1,167). A sac regression of 0-30% was observed in 4,772 (94.3%) over the first four years post-EVAR. Here, 99.6% of patients receiving the Fenestrated Anaconda™ due to unsuitable/complex anatomy for competitor devices and 76.8% based on surgeon preference had 0-30% sac regression. During years 5-9 of follow-up, all patients had 20-45% sac regression. Patient survival during the first six years post-EVAR was 100% but dropped to 77.1% in years 7-9. Survival differed between categorical patient subsets based on the indication.</p><p><strong>Discussion: </strong>The Fenestrated Anaconda™ has been proven to be a highly effective EVAR endograft. Evidence in the literature clearly demonstrates that sac regression is an accurate prognostic factor for patient survival and longevity.</p>","PeriodicalId":35950,"journal":{"name":"ASIAN CARDIOVASCULAR & THORACIC ANNALS","volume":null,"pages":null},"PeriodicalIF":0.7000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":"{\"title\":\"Correlative effect between sac regression and patient longevity following endovascular solution for abdominal aortic aneurysms: an international analysis.\",\"authors\":\"Matti Jubouri, Abdelaziz O Surkhi, Sven Zcp Tan, Damian M Bailey, Ian M Williams, Mohamad Bashir\",\"doi\":\"10.1177/02184923221129983\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Since the introduction of endovascular aortic repair (EVAR) it has become the mainstay treatment for abdominal aortic aneurysms. Several EVAR devices exist commercially, yet, the Terumo Aortic Fenestrated Anaconda™ endograft has demonstrated outstanding results. Evidence in the literature suggests that sac regression could be linked to patient survival and longevity. The main scope of this study is to evaluate sac regression and survival achieved using the Fenestrated Anaconda™ endograft and to discuss relevant literature.</p><p><strong>Materials and methods: </strong>The current study represents a nine-year cross-sectional international analysis of custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R were utilised. Pearson chi-square analysis was used to assess differences in cumulative distribution frequencies between select variables. Statistical significance for all two-tailed tests was set at <i>p </i>< 0.05.</p><p><strong>Results: </strong>A total of 5,058 patients received the Fenestrated Anaconda™ in this study, either due to unsuitable/complex anatomy for competitor devices (<i>n</i> = 3,891) or based on surgeon preference (<i>n</i> = 1,167). A sac regression of 0-30% was observed in 4,772 (94.3%) over the first four years post-EVAR. Here, 99.6% of patients receiving the Fenestrated Anaconda™ due to unsuitable/complex anatomy for competitor devices and 76.8% based on surgeon preference had 0-30% sac regression. During years 5-9 of follow-up, all patients had 20-45% sac regression. Patient survival during the first six years post-EVAR was 100% but dropped to 77.1% in years 7-9. Survival differed between categorical patient subsets based on the indication.</p><p><strong>Discussion: </strong>The Fenestrated Anaconda™ has been proven to be a highly effective EVAR endograft. Evidence in the literature clearly demonstrates that sac regression is an accurate prognostic factor for patient survival and longevity.</p>\",\"PeriodicalId\":35950,\"journal\":{\"name\":\"ASIAN CARDIOVASCULAR & THORACIC ANNALS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ASIAN CARDIOVASCULAR & THORACIC ANNALS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/02184923221129983\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ASIAN CARDIOVASCULAR & THORACIC ANNALS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02184923221129983","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3
摘要
自引入血管内主动脉修复术(EVAR)以来,它已成为腹主动脉瘤的主要治疗方法。市面上已有几种EVAR设备,但Terumo主动脉开窗Anaconda™内移植物显示出出色的效果。文献中的证据表明,囊退化可能与患者的生存和寿命有关。本研究的主要范围是评估使用feneated Anaconda™内移植物获得的囊退化和存活率,并讨论相关文献。材料和方法:目前的研究是对定制的开窗Anaconda™装置进行的为期9年的国际横断面分析。采用SPSS 28 For Windows和R软件进行统计分析。使用皮尔逊卡方分析来评估所选变量之间累积分布频率的差异。结果:在本研究中,共有5058名患者接受了开窗Anaconda™,原因可能是竞争器械的解剖结构不合适/复杂(n = 3891),也可能是基于外科医生的偏好(n = 1167)。4772例(94.3%)患者在evar后的头四年中观察到0-30%的囊性回归。在这里,由于不适合或复杂的解剖结构而接受开窗Anaconda™的患者中有99.6%,基于外科医生偏好的76.8%的患者有0-30%的囊退化。在5-9年的随访中,所有患者有20-45%的囊退化。患者在evar后的前6年生存率为100%,但在7-9年降至77.1%。基于适应症的分类患者亚群之间的生存差异。讨论:开窗Anaconda™已被证明是一种非常有效的EVAR内移植物。文献证据清楚地表明,囊退化是患者生存和寿命的准确预后因素。
Correlative effect between sac regression and patient longevity following endovascular solution for abdominal aortic aneurysms: an international analysis.
Introduction: Since the introduction of endovascular aortic repair (EVAR) it has become the mainstay treatment for abdominal aortic aneurysms. Several EVAR devices exist commercially, yet, the Terumo Aortic Fenestrated Anaconda™ endograft has demonstrated outstanding results. Evidence in the literature suggests that sac regression could be linked to patient survival and longevity. The main scope of this study is to evaluate sac regression and survival achieved using the Fenestrated Anaconda™ endograft and to discuss relevant literature.
Materials and methods: The current study represents a nine-year cross-sectional international analysis of custom-made Fenestrated Anaconda™ device. For the statistical analysis, SPSS 28 for Windows and R were utilised. Pearson chi-square analysis was used to assess differences in cumulative distribution frequencies between select variables. Statistical significance for all two-tailed tests was set at p < 0.05.
Results: A total of 5,058 patients received the Fenestrated Anaconda™ in this study, either due to unsuitable/complex anatomy for competitor devices (n = 3,891) or based on surgeon preference (n = 1,167). A sac regression of 0-30% was observed in 4,772 (94.3%) over the first four years post-EVAR. Here, 99.6% of patients receiving the Fenestrated Anaconda™ due to unsuitable/complex anatomy for competitor devices and 76.8% based on surgeon preference had 0-30% sac regression. During years 5-9 of follow-up, all patients had 20-45% sac regression. Patient survival during the first six years post-EVAR was 100% but dropped to 77.1% in years 7-9. Survival differed between categorical patient subsets based on the indication.
Discussion: The Fenestrated Anaconda™ has been proven to be a highly effective EVAR endograft. Evidence in the literature clearly demonstrates that sac regression is an accurate prognostic factor for patient survival and longevity.
期刊介绍:
The Asian Cardiovascular and Thoracic Annals is an international peer-reviewed journal pertaining to cardiovascular and thoracic medicine. Besides original clinical manuscripts, we welcome research reports, product reviews, reports of new techniques, and findings of special significance to Asia and the Pacific Rim. Case studies that have significant novel original observations, are instructive, include adequate methodological details and provide conclusions. Workshop proceedings, meetings and book reviews, letters to the editor, and meeting announcements are encouraged along with relevant articles from authors.